Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Current Oncology Reports|July 10, 2020
Medulloblastoma: an Old Diagnosis with New PromisesLuca Szalontay, Yasmin Khakoo
Behavioural Brain Research|April 16, 2004
Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's diseaseDóra Reglodi, Andrea Lubics, Andrea Tamás, et al.
Behavioural Brain Research|February 9, 2005
Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in ratsAndrea Tamás, Andrea Lubics, Luca Szalontay, et al.
Regulatory Peptides|November 3, 2004
Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in ratsDóra Reglodi, Andrea Tamás, Andrea Lubics, et al.
Oncotarget|July 5, 2014
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levelsPetra Popovics, Andrew V Schally, Luca Szalontay, et al.
Behavioural Brain Research|December 25, 2004
Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic-ischemic injuryAndrea Lubics, Dóra Reglodi, Andrea Tamás, et al.
Peptides|June 16, 2009
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162Andrea Treszl, Andrew V Schally, Stephan Seitz, et al.
The Prostate|January 3, 2013
Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasiaFerenc G Rick, Andrew V Schally, Norman L Block, et al.
Oncotarget|March 23, 2013
Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormoneMiklos Jaszberenyi, Andrew V Schally, Norman L Block, et al.
Anti-Cancer Drugs|August 29, 2012
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-IIKaroly Szepeshazi, Andrew V Schally, Ferenc G Rick, et al.
Pageof 5